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Abstract
Germline genetics, gender and hormonal-signaling pathways are all well described modifiers of cancer risk and progression.
Although an improved understanding of how germline genetic variants interact with other cancer risk factors may allow
better prevention and treatment of human cancer, measuring and quantifying these interactions is challenging. In other
areas of research, Information Theory has been used to quantitatively describe similar multivariate interactions. We
implemented a novel information-theoretic analysis to measure the joint effect of a high frequency germline genetic variant
of the p53 tumor suppressor pathway (MDM2 SNP309 T/G) and gender on clinical cancer phenotypes. This analysis
quantitatively describes synergistic interactions among gender, the MDM2 SNP309 locus, and the age of onset of
tumorigenesis in p53 mutation carriers. These results offer a molecular and genetic basis for the observed sexual
dimorphism of cancer risk in p53 mutation carriers and a model is proposed that suggests a novel cancer prevention
strategy for p53 mutation carriers.
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Introduction
The p53 stress response pathway functions as a critical tumor
suppressor pathway, as demonstrated by the observation that the
p53 gene is one of the most commonly mutated genes in human
tumors [1]. Furthermore, both mice and humans harboring a
germ-line inactivating mutation in just one allele of the p53 gene
develop tumors early in life and at very high frequencies [2-5].
Humans harboring a germ-line inactivating p53 mutation make
up 50% of the members of the Li-Fraumeni cancer predisposition
syndrome. The age of onset of tumor formation in human p53
mutation carriers has been shown to be modified in four
independent studies by a high frequency single nucleotide
polymorphism in the promoter of the Mdm2 oncogene (MDM2
SNP309, T/G) [6-9]. The G-allele of SNP309 increases the DNA
binding affinity of the transcriptional activator Sp1, which results
in higher levels of MDM2 mRNA and protein in human cells and
tissues [6,10-12]. Higher levels of MDM2 lead to the attenuation
of the p53 pathway, in concordance with the role of MDM2 as a
key negative regulator of p53 [13]. In p53 mutation carriers, it was
shown in three independent reports that individuals with the G-
allele of SNP309 are diagnosed with cancer on average seven to
fifteen years earlier than those p53 mutation carriers homozygous
for the T-allele (Table 1) [6-8]. It was proposed that the high levels
of MDM2 resulting from the G-allele of SNP309, together with
the mutant p53 allele, produce a severely weakened p53 tumor
suppressor pathway and result in a higher mutation rate, poorer
DNA repair processes, and reduced apoptosis, leading to faster
and more frequent tumor formation [14].
Recently, studies with sporadic cancers (162 Ashkenazi Jewish
lymphoma patients, 969 Finnish and 164 Italian colorectal cancer
patients, 105 German sarcoma patients, 341 Norwegian non-small
cell lung cancer patients and 658 Ashkenazi Jewish breast cancer
patients) have demonstrated that the effects of the G-allele of
MDM2 SNP309 locus on tumorigenesis can be modified by two
additional variables; namely gender and the primarily female-
specific hormone, estrogen [15-19]. Specifically, the G-allele of
MDM2 SNP309 was shown to accelerate tumorigenesis and
increase cancer risk in women and not in men for colorectal
cancer, diffuse large B-cell lymphoma, lung cancer and for highly
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estrogen receptor positive (.50% of tumor cells), but not for
estrogen receptor negative, invasive ductal carcinoma of the
breast[16,18,19]. This was shown to result in the enrichment of
individuals with the G-allele in pre-menopausal women with these
cancers, when compared to either post-menopausal women or
men with the same cancers. Recently, Hu et al. provided evidence
for a possible molecular mechanism for how the G-allele of
SNP309 could accelerate tumor formation in this gender-specific
and estrogen dependent manner, by demonstrating that the
primarily female-specific hormone, estrogen, preferentially stimu-
lated transcription of the MDM2 gene with the G-allele of
SNP309 [20].
Interestingly, two independent studies have also defined gender
to be a modifying factor of cancer risk in p53 mutation carriers
[21,22]. Specifically, female p53 mutation carriers were shown to
be at greater risk for developing cancer than their male
counterparts. For example, by 20, 30, 40, and 50 years of age,
the female carriers showed respective cumulative risks of 18%,
49%, 77% and 93% for developing a first cancer, while the male
carriers showed risks of 10%, 21%, 33% and 68% [22]. The
increased risk in female carriers could not be explained by the high
incidence of gender-specific cancers, as the differences remained
after the exclusion of cases of breast, ovarian, and prostate cancers.
Although the possible involvement of estrogen in increasing cancer
risk in female carriers was discussed, this hypothesis remains
untested.
It is intriguing to hypothesize that the SNP309 locus could
contribute to the increased cancer risk observed in female carriers
though the preferential estrogen-dependent stimulation of MDM2
transcription from the G-allele of SNP309. If true, estrogen
manipulation could be incorporated in prevention strategies for
p53-mutation carriers with the G-allele of MDM2 SNP309. Such
patients have limited cancer prevention strategies. In this report,
the hypothesis that the primarily female specific hormone,
estrogen, could affect tumorigenesis in p53-mutation carriers is
tested though exploring possible interactions between MDM2
SNP309 locus and gender upon the age-dependent tumor
incidence.
There has been increasing interest in the development of
statistical tools to uncover such interactions, as between genotype
and gender, and their effect upon complex phenotypes, such as
age-dependent tumor incidence. Recent methods, both parametric
and non-parametric, include neural networks [23], recursive
partitioning methods [24], combinatorial partitioning methods
[25], multifactor-dimensionality reduction [26] and multi-locus
regression [27,28]. These methods are tailored to address specific
questions about the nature of multi-locus interactions and invoke
different assumptions about the underlying model generating these
data. Here we employ a novel information-theoretic framework to
address the specific question of whether gender and the MDM2
SNP309 locus interact synergistically or redundantly with respect
to the age of tumor incidence in p53 mutation carriers. The
optimal properties of information-theoretic terms in assessing
variability and correlation between multiple variables are familiar
to the machine learning and statistics communities but perhaps not
well known in fields of epidemiology and medical statistics. An
additional advantage in the context of this present study is that the
principles of information theory allow us to study complex
phenotypes expressed as real numbers (i.e. age of onset of cancer
as opposed to the binary case/control scenario) by defining the
optimal partitioning, or binning, of the continuous phenotype
data.
Methods
p53 Mutation Carriers (M.D. Anderson Cancer Center)
88 individuals who are members of Li-Fraumeni syndrome
(LFS) families (34 total) with known germline mutations in one
allele of p53 were previously genotyped for MDM2 SNP309 [6].
66 of these have been diagnosed with at least one cancer. Of the
LFS families included in this study, 12 were ascertained through
systematic studies of sequential childhood soft tissue sarcoma (7
families) and osteosarcoma (5 families) patients. The remaining
families consisted of patients referred to M. D. Anderson for
research or clinical studies with a personal or family history of
cancers of the type found in LFS. The largest family contributes 14
samples to this study; 16 families contribute a single individual.
p53 Mutation Carriers (French LFS Network)
Sixty-one affected or unaffected germ-line p53 mutation
carriers, from 41 unrelated LFS families were previously
genotyped for MDM2 SNP309 [7]. Clinical characteristics of
the families and description of the mutations were available upon
request. Forty-one affected germ-line p53 mutation carriers were
incorporated into this study. The largest family contributes 3
affected individuals to this study; 27 families contribute a single
affected individual.
p53 Mutation Carriers (Dutch/Finnish Study)
One hundred and eight patients from 87 LFS or LFS-like
families were previously screened for p53 mutations and
genotyped for MDM2 SNP309 [8]. Ninety-seven were screened
at the Family Cancer Clinic of the Netherlands Cancer Institute
and 11 at the Helsinki University Central Hospital. Thirty-six
Table 1. Characteristics of three patient populations used to define MDM2 SNP309 as a modifier of tumorgenisis in p53-mutation
carriers.
Number of
Affected
Carriers
Earlier Average
Age of Tumor
Diagnosis for
G-allele Carriers
(years, reported
p-value) Orignal Reference
Number of
Carriers with a
Cancer other
than Breast,
Ovarian or
Prostate
Number of
Females
Number
of Males
p53 Mutation
Carriers
M.D. Anderson Cancer Center 66 7 (p = 0.031) Bond, Wu et al., 2004 48 18 30
French LFS Network 42 10.3 (p,0.05) Bougeard et al., 2006 29 16 13
Dutch/Finnish Study 36 15.8 (p = 0.005) Ruijs et al., 2006 24 10 14
doi:10.1371/journal.pone.0001951.t001
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affected individuals from 19 families carried known germline
mutations in the p53 gene and were incorporated into this study.
Information-Theoretic Analysis
Given a variable, say X, which can exist in one of KX states, and
its set of associated probabilities {p(X= x1),p(X= x2)...p(X= xK)},
then Shannon’s entropy H X½ ~{P
KX
i~1
p xið Þlog2p xið Þ provides a
general non-parametric measure of the variability, or information
content, of X. This measure of information content is the only
quantity that satisfies certain reasonable criteria such as H[X]
ought to be an increasing function of KX if all the probabilities are
equal. The joint entropy for two variables measured together,
say X and Y, can also be appropriately defined, H X ,Y½ ~
{
PKX
i~1
PKY
j~1
p xi,yj
 
log2p xi,yj
 
where p(xi,yj) is the probability for
the two events X= xi and Y= yj co-occurring. It can be shown that
the following inequality for the joint entropy must always apply,
H[X,Y]#H[X]+H[Y], with equality if and only if X and Y are
independent variables p(xi,yj) = p(xi)p(yj), i.e. the joint entropy will
always be less than the sum of the individual entropies if there is
any dependence, or correlation, between the two variables. The
measure of statistical dependency between two variables, X and Y,
is then simply captured by the reduction in total entropy when the
two variables are measured together, i.e. Shannon’s mutual
information I X ;Y½ ~H X½ zH Y½ {H X ,Y½ ~P
KX
i~1
PKY
j~1
p xi,yj
 
log2
p xi ,yjð Þ
p xið Þp yjð Þ . Note that this does not invoke any of the linear
(Gaussian) assumptions required by other measures such as
Pearson’s correlation. This definition can also be equivalently
written as I[X;Y] =H[X]2H[XIY] =H[Y]2H[YIX], where the
conditional entropy H[XIY] is defined as H HjY½ ~{P
KX
i~1
PKY
j~1
p
xi,yj
 
log2p xijyj
 
, making it evident that I[X;Y] can be
interpreted as the reduction of the variability of X due to
knowledge of Y, and vice versa.
Data analysis using discrete versions of information-theoretic
expressions, as defined in the previous paragraph, requires
creating bins that discretize continuous values. For example, the
real number representing the age of diagnosis of cancer has to
binned into one of several groups, essentially a task in data
compression. We can draw upon information theory and note that
the least biased partitioning of any dataset is given by the principle
of maximum entropy, i.e., partitioning into equally populated bins
or quantiles. In this case any information-theoretic expression
calculated from the binned data has the important and desirable
property that it is invariant to invertible coordinate transforma-
tions, e.g. multiplying all the ages by a constant factor should not
affect the mutual information with the SNP variable. A common
problem with quantizing real numbers into bins is deciding how
many bins to use, and to this end we again appeal to information
theory. A sensible criterion can be gleaned from the observation
that if we try to measure the mutual information between two
finitely-sampled independent distributions then employing too
many bins will over-fit the data, giving rise to a non-zero value of
mutual information, even when extrapolated to the infinite sample
limit [29]. On the other hand, compressing the data into too few
bins over-smoothes the data, and potentially loses important
structure in these data. Thus there ought to be an optimal trade-off
between over-fitting and information compression. We determined
that the optimal number of bins in our dataset were three, and to
establish this, the mutual information values were first calculated
with randomly shuffled data, to destroy any correlation, and it was
observed that when the number of bins was increased from three
to four and higher, the extrapolated mutual information values
was no longer zero within error bars. Thus by restricting the
number of bins we implicitly incorporate a sample-size dependent
penalty for over-fitting of the data. Further explicit details on this
and other possible methods of estimating mutual information are
given in [29,30]
Synergistic Information
These information-theoretic concepts can be extended to
naturally probe questions of statistical dependencies amongst
more than two variables. In particular, levels of synergy and
redundancy amongst three variables can be quantified in a
principled manner, and have recently been formulated in the
context of analyzing correlations between neurons [29,30]. If we
use the definition of synergy between two variables X,Y with
respect to a third variable Z, as how much extra information X and
Y together provide about Z than by X and Y separately, then we
are immediately lead to the natural formulation of synergistic
information as S(X,Y;Z) = I(X,Y;Z)-I(X;Z)-I(Y;Z) where
I X ,Y ;Zð Þ~P
KX
i~1
PKY
j~1
PKZ
k~1
p xi,yj ,zk
 
log2
p xi ,yj ,zkð Þ
p xi ,yjð Þp zkð Þ. The synergis-
tic information thus reveals how much of the variability of Z is
reduced by knowing both X and Y together than knowing them
separately and thus rigorously quantifies the non-independent
effects of both X and Y on Z. This mathematical formulation of
synergy can be generalized naturally to more than three variables.
Statistical Analysis
It may not be clear how to accurately interpret information-
theoretic values determined from empirical distributions, especial-
ly as statistical fluctuations grow with decreasing sample size.
Furthermore, due to the concavity of Shannon’s entropy, finite
sampling induces a negative bias in the empirical entropy and a
positive bias in the empirical mutual information [29]. These
problems necessitate generation of p-values to the calculated
information-theoretic values against a specified null hypothesis. In
the case of mutual information, the null hypothesis was that no
statistical dependence existed between a single variable (either
SNP or gender) and age of diagnosis, i.e., the joint probability is
simply a product of the marginals, p(variable,age) = p(variable)p(age).
In the case of synergistic information, the null hypothesis was that
no correlation existed between two variables and age of diagnosis
while preserving the correlation between the two variables, i.e.
p(SNP,gender,age) = p(SNP,gender)p(age), p(SNP,age) = p(SNP)p(age) and
p(gender,age) = p(gender)p(age). The p-values were determined by a
Monte Carlo permutation test. A minimum number of 106
permutations were required to generate a confidence interval
range of less than 0.005 at p-value 0.05.
A two-sided Mann-Whitney test was employed to determine the
statistical significance of the difference in the median age of tumor
diagnosis between the groups with and without the G-allele of
SNP309. Strictly speaking, the Mann-Whitney test is a non-
parametric assessment of whether two sets of data are drawn from
the same distribution, but if the two sets of data have roughly the
same shape then it is justified to interpret the results of the test as a
statement on whether the median in the two groups are statistically
not different. A permutation test was employed to determine the
significance of the difference in the average age of tumor diagnosis
between the two groups [6]. Both a Kolmogorov-Smirnov test and
MDM2 SNP309, p53, Gender
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a Cramer-Smirnov-Von Mises test were utilized to determine the
significance of the difference in the distributions of age of diagnosis
between the groups with and without the G-allele of SNP309. By
employing all of these tests for significance, many of the
assumptions inherent in any one test are eliminated.
Results
To test the effects of, and the interactions between, gender and
the alleles at the MDM2 SNP309 locus gene upon tumorigenesis
in p53 mutation carriers, all 144 p53 mutation carriers, who were
genotyped at the MDM2 SNP309 locus previously [6-8], were
studied (Table 1). Collectively, when the 144 individuals were
separated into the different genotypes of the SNP309 locus,
individuals who carried the G-allele in either the heterozygous or
homozygous state (n = 81), showed a very significant 11-year
earlier average age of first tumor onset compared to individuals T/
T (n= 63) in genotype (T/T individuals, average is 33 years of age
versus 22 years of age in G/G and T/G individuals, p = 0.0006,
Mann Whitney Test). A significant earlier average age of first
tumor onset among G-allele carriers was also seen in both females
and males. Males who carried the G-allele in either the
heterozygous or homozygous state (n = 35), showed a significant
12-year earlier average age of first tumor onset compared to males
T/T (n= 23) in genotype (p = 0.0436, Mann Whitney Test).
Females who carried the G-allele in either the heterozygous or
homozygous state (n = 46), showed a significant 10-year earlier
average age of first tumor onset compared to females T/T (n= 40)
in genotype (p= 0.0223, Mann Whitney Test).
In order to directly compare the age dependent incidence of
cancer between males and females, individuals who developed
primarily gender-specific cancers (breast and prostate cancer) were
excluded from this analysis, leaving STS, osteosarcomas and
leukemias as the major tumor types analyzed in both genders
(Figure 1A and B). Of the remaining 101 individuals, 57
individuals were male and 44 were female (Table 1). The mutual
information shared between gender, the G and T alleles of MDM2
SNP309 and the age of first tumor diagnosis were calculated and
the results are presented in Figure 1C. As expected from the
previously published analyses of these populations [6-8], the
MDM2 SNP309 locus affects the age of tumor diagnosis in a
significant manner as demonstrated by a significant level of mutual
information (0.10 bits, p = 0.007, Permutation Test). In contrast to
what was expected from the previous assessments of overall cancer
risk in p53 mutation carriers [21,22], gender alone did not show a
significant level of mutual information with the age of first tumor
diagnosis (0.002 bits, p = 0.9, Permutation Test). Indeed, when the
101 individuals were separated into the different genotypes of the
SNP309 locus, individuals who carried the G-allele in either the
heterozygous or homozygous state, showed a very significant 12-
year earlier average age, and 17-year median age of first tumor
onset compared to individuals T/T in genotype (T/T individuals,
average is 30 years of age, ranging 1 to 71 years, versus 18 years
of age in G/G and T/G individuals, ranging from 1 to 59 years,
Figure 1D and Table 2). Statistical significance of this 12-year
earlier average age, and 17-year earlier median age of tumor onset
was measured using a permutation test and a Mann-Whitney test
(see Materials and Methods, p = 0.0008 and p= 0.0015, Table 2).
Furthermore, the significance of the difference in the distributions
of the ages of tumor diagnosis between G-allele carriers and
individuals T/T in genotype, as seen in Figure 1D, was measured
using two approaches: the Kolmogorv-Smirnov Test and the
Cramer-Smirnov-Von Mises Test. Both tests supported the
significance of these differences by yielding p-values 0.0091 and
0.0046, respectively (Table 2). In contrast, when the 101
individuals were separated based on gender alone, no significant
differences in the average age of tumor onset were seen.
Specifically, female p53-mutation carriers were diagnosed on
average at 23 years of age (ranging from 1 to 71 years of age)
compared to the male carriers who were diagnosed on average at
24 years of age (ranging from 1 to 59 years of age, Figure 1E and
Table 2).
As mentioned above, one advantage of an information-theoretic
analysis of interactions is that non-additive interactions can be
detected and quantified. Interestingly, this analysis revealed that
the MDM2 SNP309 locus and gender taken together interact to
affect the age of tumor diagnosis in a non-additive, synergistic
manner, as demonstrated by the measured 0.06 bits of significant
synergistic information (p= 0.05, Permutation Test). This suggests
that the well-defined modifying effect of the MDM2 SNP309 locus
upon the age of first tumor onset in p53-mutation carriers (Table 1)
could be significantly different between the genders. To test this,
the interaction of the alleles of MDM2 SNP309 with the age of
tumor diagnosis was measured for both genders by calculating
their respective mutual informations. Interestingly, by this
measure, the MDM2 SNP309 locus only significantly interacts
with the age of tumor diagnosis in female carriers and not in male
carriers. Specifically, in female carriers, the MDM2 SNP309 locus
and the age of tumor diagnosis share a significant 0.2 bits of
mutual information (p = 0.014, Figure 2A). However, in male
carriers, the 0.114 bits of mutual information measured does not
reach significance with a p-value of 0.06.
When separated into the different genotypes of the SNP309
locus, the 23 females who carried the G-allele in either the
heterozygous or homozygous state, show a significant 16-year
earlier average age, and 23-year median age of tumor onset
compared to the 21 females T/T in genotype (T/T females,
31 years of age, ranging 2 to 71 years, versus 15 years of age in
G/G and T/G females, ranging from 1 to 54 years, p = 0.007 and
p= 0.0037, Figure 2B and Table 2). Their respective distributions
of the ages of tumor diagnosis also significantly differ, as measured
by the Kolmogorov-Smirnov Test and Cramer-Smirnov-Von
Mises Test (p = 0.0275 and 0.0077, Table 2). As predicted by the
information-theoretic analysis the differences between the male G-
allele carriers and the males T/T in genotype are much weaker.
When separated into the different genotypes of the SNP309 locus,
males who carried the G-allele in either the heterozygous or
homozygous state, showed a significant 10-year earlier average age
of tumor onset compared to males T/T in genotype (T/T males,
30 years of age, ranging 1 to 55 years, versus 20 years of age in
G/G and T/G females, ranging from 1 to 54 years, p = 0.0285,
Figure 2C and Table 2). However, the measured significance of
the differences in the medians and distributions in males were just
boarder-line significant with p-values of 0.0672, 0.0478 and
0.0469 respectively (Table 2). Thus the p-values calculated in
several different ways were 5-10 fold weaker for the impact of the
G-allele upon the age of onset of first tumors in males than
females.
Discussion
In this report, the statistical dependencies of the MDM2
SNP309 locus and gender upon the age of first tumor onset in
p53 mutation carriers were determined using a novel quantita-
tive information-theoretic approach. The three patient popula-
tions that were originally used to define MDM2 SNP309 as a
modifier of tumorigenesis in p53 mutation carriers were
analyzed (Table 1). The analysis revealed a significant level of
MDM2 SNP309, p53, Gender
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mutual information between the MDM2 SNP309 locus and the
age of first tumor onset, but not between gender and the age of
tumor onset (Figure 1). The information-theoretic approach
allowed for the probing of statistical dependencies among all
three variables (the alleles of MDM2 SNP309, gender and the
age of first tumor onset). Interestingly, the MDM2 SNP309 locus
and gender taken together were shown to interact and affect the
age of non-gender specific tumor diagnosis in a non-additive,
synergistic manner (Synergistic Information = 0.06 bits;
p = 0.05). In females, the MDM2 SNP309 locus and the age of
tumor diagnosis share significant mutual information whereas, in
males, the level of mutual information measured did not quite
reach significance (Figure 2). In other words, the analysis of the
three variables in this study revealed that gender does in fact play
a role in age-dependent incidence but only when information is
also provided about the allelic form of the MDM2 SNP309
locus. This is likely due to the observation that only the G-allele
at MDM2 SNP309 is stimulated to produce more MDM2
mRNA and protein in the presence of estrogen [20]. Standard
statistical tests measuring the significance of the differences both
in the mean and median ages of first tumor onset and in the
distributions of the ages of tumor diagnosis between G-allele
carriers and individuals T/T in genotype validated these
observations (Table 2).
As mentioned above, the information-theoretic approach can
probe questions of statistical dependencies among more than two
variables and can quantify levels of synergy and redundancy.
Large-scale genetic and epidemiological studies increasingly have
acknowledged that variables interact in a non-additive manner
with respect to risk of disease, i.e. the variables do not act
independently of each other. Highlighting these dependencies is
critical in understanding how disease risk can be modified subtly
by a hidden variable and can explain why different epidemiolog-
ical studies can report different conclusions based on viewing a
single variable [17]. Furthermore, the identification and quanti-
fication of synergistic interactions also can shine a light on new
Figure 1. An information-theoretic analysis reveals a significant level of mutual information between the MDM2 SNP309 locus, but
not gender, and the age of tumor onset. In order to compare the age dependent incidence of cancer between males and females, individuals
who developed primarily gender-specific cancers were excluded from this analysis, leaving STS, osteosarcomas and leukemmias as the major tumor
types analyzed as depicted in the pie charts for both males (A) and females (B). (C) The bar graph depicts the bits of mutual information between
the MDM2 SNP309 locus and the age of tumor onset, gender and the age of tumor onset and lastly between all three variables. The associated p-
values are depicted below. (D) The cumulative incidence of tumor diagnosis for both the individuals T/T in genotype (black squares) and T/G or G/G
(SNP309) in genotype (grey diamonds) is plotted as a function of age. A square or a diamond represents at least one individual. (E) The cumulative
incidence of tumor diagnosis for both males (black squares) and females (grey diamonds) is plotted as a function of age.
doi:10.1371/journal.pone.0001951.g001
MDM2 SNP309, p53, Gender
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Figure 2. The G-Allele of SNP309 Associates with an Accelerated Age of Diagnosis of Non-Gender Specific Tumors in Female but
not in Male p53 Mutation Carriers. (A) The bar graph depicts the bits of mutual information between the MDM2 SNP309 locus and the age of
tumor onset in females and in males. The associated p-values are depicted below. The MDM2 SNP309 locus and the age of tumor diagnosis share
significant mutual information only in females and not in males. Statistical significance is represented by the black labeling of the bar graph and the
p-values depicted below. The cumulative incidence of all non-gender specific tumor types for both the individuals T/T in genotype (black squares)
and T/G or G/G in genotype (grey diamonds) is plotted as a function of age for females (B) and males (C). A square or a diamond represents at least
one individual.
doi:10.1371/journal.pone.0001951.g002
Table 2. The effect of the MDM2 SNP309 locus and gender on the age of diagnosis in p53 mutation carriers.
Number
Average
Age
Median
Age
Permutation Test for
Difference in Average
(p-value)
Mann-Whitney
Test (p-value)
Kolmogorv-
Smirnov Test
(p-value)
Cramer-Smirnov-
Von Mises Test sr
(p-value)
MDM2 SNP309
Locus
T/T 43 30 32 0.0008 0.0015 0.0091 0.0046
SNP309 58 18 15
Gender Males 57 24 19 0.7468 0.5216 0.3348 0.3989
Females 44 23 15
Males T/T 22 30 33 0.0285 0.0672 0.0478 0.0469
SNP309 35 20 17
Females T/T 21 31 32 0.007 0.0037 0.0275 0.0077
SNP309 23 15 9
doi:10.1371/journal.pone.0001951.t002
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biological mechanisms, such as cross talk between two signaling
pathways. However, as yet, there has been no rigorous definition
and thus, no quantification of such synergistic interactions.
Information theory and the methods detailed here form a natural
framework to address these issues of statistical dependencies
among variables while invoking no parametric assumptions.
In conclusion, the information-theoretic analysis of the statistical
dependencies of the MDM2 SNP309 locus and gender upon the
age of tumor onset in p53 mutation carriers suggests that the G-
allele of SNP309 functions primarily in female p53 mutation
carriers to accelerate tumor formation, thereby providing a
potential genetic basis for observed sexual dimorphism in cancer
risk [21,22]. These observations in conjunction with the
observations that both pre-pubescent and post-pubescent females
have higher levels of estrogen [33,34], and that estrogen has been
shown to preferentially stimulate the transcription of MDM2 from
the G-allele [20], provide a reasonable hypothesis; the G-allele of
the MDM2 SNP309 locus could contribute to the increased
cancer risk observed in female p53 mutation carriers through the
preferential estrogen-dependent stimulation of transcription of the
MDM2 gene. If true, this model predicts that estrogen reduction
or withdrawal from G-allele MDM2 SNP309 patients could be
incorporated in prevention strategies for p53-germlinc carriers, for
whom cancer prevention strategies are limited, much as they have
been successfully implemented for BRCA-mutation carriers
[35-37].
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